Eight Things Rheumatologists Should Know About Medical Marijuana
Eight Things Rheumatologists Should Know About Medical Marijuana
1. Marijuana is the dried leaves and flowers of the plant Cannabis sativa that contains over 450 different compounds. Two of these, THC and cannabidiol, are of greatest interest at present.
Medicinal and psychoactive properties have been attributed to flowering plants of the genus Cannabis for thousands of years, but herbal cannabis remains mostly outside mainstream medicine. Its clinical status is prejudiced by the fact that 4% of the global population uses (or misuses) marijuana as a “recreational” drug.
At least 70 of the 450 compounds in the plant Cannabis sativa are classified as phytocannabinoids, but the therapeutic effects of these molecules are not yet fully understood.1 Two are of particular significance to medicine:
• Tetrahydrocannabinol (THC), produced by the action of heat on the acid precursor of delta-9-tetrahydrocannabinol (D9-THC), is known for its psychoactive and pain-relieving properties.
• Cannabidiol has potential therapeutic application due to its effect on immunological function and its potential to counteract the negative psychoactive effects of THC.
2. Receptors that engage cannabinoid molecules are ubiquitous throughout the human body.
These receptors are located in the central and peripheral nervous system, as well as on immune, bone, and synovial cells. They interact with cannabinoid molecules that can be found in three setings:
1) Synthetic tricyclic terpenes;2
2) Phytocannabinoids, including THC and cannabidiol;
3) Endocannabinoids, endogenenous ligands derived from the breakdown of phospholipids in a pathway distinct from the inflammatory prostaglandin pathway.3
Cannabinoid actions are mainly mediated via the two best-explored endocannabinoid receptors. This is not a simple on/off process, but rather a complex phenomenon involving endogenous and exogenous ligands, cross-reactions with non-cannabinoid receptors, and plasticity of response dependent upon local tissue characteristics or the presence of other molecules such as opioids.4
3. In the setting of arthritis, the endocannabinoid system is activated locally in response to tissue changes and functions as an endogenous pain modulator.
Examined mainly in laboratory studies, the endocannabinoid system has an impact on pain mechanisms, immune function, inflammation, and bone health. Many effects are still poorly understood, and are the subject of active study.
Cannabinoids exert their physiological effect through binding to two G protein-coupled receptors (CB1 and CB2) as well as a recently described putative third receptor, GPR55.5 Animal study has shown that joints affected by both degenerative and inflammatory arthritis actively express these cannabinoid receptors and produce endocannabinoids.
• In a rat model of osteoarthritis, exposing the CB1 receptor to the agonist arachidonyl-2-chloroethylamide (ACEA) resulted in increased synovial blood flow and reduced hypersensitivity of joint nociceptors (pain sensing neurons).6
• Interestingly, a paradoxical response was observed for the response of the CB2 receptor. An agonist to the CB2 receptor inhibited nociceptor activity in control (normal) joints, but caused sensitization of osteoarthritis joint afferents.7 These paradoxical findings emphasize the complexity of the cannabinoid system.
• Human synovial fluid from osteoarthritis and rheumatoid arthritis joints, but not from normal controls, contained the endocannabinoids anandamide and 2-arachidonyl glycerol, confirming that endocannabinoids are synthesized following tissue injury.8
The immunosuppressive and anti-inflammatory actions of the cannabinoid system are less clearly understood, but believed to be mediated via the CB2 receptor, with effects on apoptosis, inflammatory cell proliferation and trafficking, cytokine production and regulation of T cells.9 The postulated effects of CBD are both anti-inflammatory and anti-oxidative.10
4. Many rheumatology patients may seek cannabinoids to relieve pain, but solid evidence for effectiveness is lacking.
“Severe pain” is cited as the most common reason persons in North America provide when using herbal cannabis medically. Commonly, they identify musculoskeletal conditions as the specific medical condition causing the pain.11,12 As rheumatic diseases are not curable, many patients may self-medicate with herbal cannabis under the impression that it is a safe complementary treatment, encouraged by the current societal perception of effect.
However, to date, not a single published randomized controlled trial has examined the dosing, efficacy, or side effect profile of herbal cannabis in patients with rheumatic diseases.13 The only sources for information about the effects of herbal cannabis or similar compounds in rheumatic diseases are:
• anecdotal reports,
• two small epidemiological studies,14, 15
• a single study in patients with rheumatoid arthritis of the oro-mucosal spray of nabiximols, a combination of D9-THC and cannabidiol,16 and
• two studies of nabilone, a synthetic analogue of THC, in fibromyalgia.17,18
5. The groundswell of advocacy driving the use of medicinal herbal cannabis is contrary to medical opinion.
Herbal cannabis has been catapulted into disease management by a groundswell of public advocacy, propelling regulatory bodies worldwide to consider legalizing herbal cannabis for medicinal use. This was done irrespectively of the limited scientific basis to support statements about either effect or risk. Thus, physicians may be required to provide care for patients who self-medicate with herbal cannabis or request guidance regarding potential use of this agent.
Recent surveys report that physicians lack confidence in their knowledge of cannabinoids in general, and in their perceived competence to advise patients effectively about use.12
• In a survey of family physicians in Colorado, only 19% thought that physicians should recommend medical marijuana, and 92% reported a need for more education.12
• Two thirds of Canadian rheumatologists expressed poor confidence in their knowledge of cannabinoid medical use. Fully 70% stated that there is currently no role for herbal cannabis in the treatment of rheumatic complaints.19
It is also increasingly recognized that sanctioning use of herbal cannabis for therapeutic reasons is currently provided by a small number of physicians for the majority of patients.12 In Colorado, 15 physicians accounted for almost half of recommendations for medical marijuana. Motives for this medical behavior should be questioned, and raise ethical concerns.
6. Smoking cannabis cannot be recommended.
While herbal cannabis may be either ingested or inhaled, inhalation is the preferred method of administration by most users as inhaled cannabis acts rapidly within a few minutes. However, smoking cannabis is not recommended because:
• It delivers noxious compounds such as polycyclic aromatic hydrocarbons, tar, and carbon monoxide. The risk for lung cancer has been debated, but with increasing evidence for true risk when studies have been controlled for cigarette smoking.20-22 In a longitudinal study of Swedish military conscripts followed for 40 years from the ages of 18 to 20, the risk for lung cancer was doubled if they had used cannabis on at least 50 occasions (hazard ratio 2.12, 95% CI 1.08 – 4.14).22
• It is impossible to estimate the dose delivered. Plasma concentrations of THC are extremely variable after smoking a “joint.” Blood levels after smoking 0.5-1.0 grams of dried substance vary between 7-100ng/mL, and are affected by the frequency, depth, volume and holding time of inhalation as well as the concentration of THC in the herbal product.23, 24 The THC concentration in illicit marijuana has doubled over the past decade, with measured concentrations varying between 1 to 30%,25 and thus the bioavailable concentrations of THC can vary from 2 to 56%.26 There is also discordance between the measured THC plasma peak and the maximum subjective psychoactive effects which occur an hour later, and can be augmented by opioids.
Oral administration could be preferred, offering a more delayed effect, lower peak plasma levels, more protracted pharmacologic effects, and fewer psychoactive effects that may lead to abuse.27 However, gastrointestinal absorption is erratic and much of the ingested cannabinoid is eliminated by first-pass metabolism in the liver.27
7. Contrary to common belief, herbal cannabis is not an innocuous substance, either for short- or long-term use, and its effects undermine the primary goals for treatment of rheumatic pain, namely reduction of symptoms and maintenance of function.
• Even in regular recreational users, acute administration impairs reaction time, selective attention, short-term memory, and motor control for up to 5 hours, with increasing effects for increasing doses.28 Acute cannabis use was associated with at least a doubling of risks for serious and fatal motor vehicle collisions according to a recent systematic review and meta-analysis of 9 studies involving 49,000 participants.29 Health Canada has warned that the ability to drive or perform activities requiring alertness or coordination may be impaired for up to 24 hours after consuming herbal cannabis.30 This risk may be compounded by the presence of other medications, especially analgesics.
• Hypotension and tachycardia shown to follow acute administration of herbal cannabis could compromise cardiovascular health in rheumatology patients with underlying heart disease, and be an added risk for cardiovascular events.31 Acute cannabis use increases the risk for myocardial infarction five-fold and reduces the exercise capacity of those with angina pectoris by half.
• Cannabis has adverse acute and chronic effects on mental health. The immediate psychiatric effects include acute anxiety and agitation, suicidal ideation, and acute psychosis.32, 33 The long-term effect on mood and especially depression are less clear, but evidence is increasing that depression is more prevalent in current cannabis users.34 Herbal cannabis is well recognized to aggravate or unmask serious psychiatric disease such as psychosis and schizophrenia.35 The addictive potential is another risk: Over a 3 year period the cumulative incidence of cannabis dependence was 37.2% (95% CI 30.7-43.8%) for young recreational users.36 Once a person is addicted to a substance, potential for use of other addictive substances remains a concern, with the initial substance acting as a gateway drug. Finally, recreational use of cannabis could result in working memory deficits that is associated with various subcortical neuroanatomical changes.37
8. How can physicians advise or care for patients with rheumatic disease who are using or proposing to use herbal cannabis for pain relief?
• Consider their motives with careful scrutiny. Many persons using marijuana for medical reasons are former recreational users. Is the patient misusing a medical diagnosis to justify use primarily for non-medical reasons?12, 14, 15
• Remain empathic and caring, but inform patients about the lack of sound evidence for either positive or negative effects of herbal cannabis in rheumatic conditions, adding that the long-term risks are troubling and have not been fully explored.
• Advise patients not to drive for at least 24 hours after using marijuana.
• Tell patients that while there are no grounds on which to recommend herbal cannabis use for rheumatic disease, numerous other pain-management options can be explored.
Physicians, rheumatologists in particular, must be proactive in voicing concerns about the current increasing use of herbal cannabis for treatment of rheumatic complaints, and advocate for further study of individual cannabinoid molecules using standard scientific methods to control dosing and assess efficacy and safety.
1. ElSohly MA and D.Slade. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci (2005) 78:539-548.
2. Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol (2006) 147 Suppl 1: S163-171.
3. Cravatt BF and Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behavior. J Neurobiol (2004) 61: 149-160.
4. Anand P, Whiteside G, Fowler CJ et al. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev (2009) 60:255-266.
5. Howlett AC. A short guide to the nomenclature of seven-transmembrane spanning receptors for lipid mediators. Life Sci (2005) 77:1522-1530.
6. Baker CL and McDougall JJ The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol (2004) 142:1361-1367.
7. Schuelert N, Zhang C, Mogg AJ, et al., Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage (2010) 18:1536-1543.
8. Richardson D, Pearson RC, Kurian N, et al., Characterisation of the cannabinoid receptor system in synovial tissue and fluid in patients with osteoarthritis and rheumatoid arthritis. Arthritis Research & Therapy (2008) 10: R43.
9. Klein TW, Newton CA, and H Friedman. Cannabinoids and the immune system. Pain Res Manag (2001) 6:95-101.
10. Zuardi AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Rev Bras Psiquiatr (2008) 30: 271-280.
11. Health Canada, Marihuana for Medical Purposes - Statistics. , (2010
12. Kondrad E and A Reid. Colorado family physicians' attitudes toward medical marijuana. J Am Board Fam Med (2013) 26:52-60.
13. Fitzcharles MA, McDougall J, Ste-Marie PA et al. Clinical implications for cannabinoid use in the rheumatic diseases: potential for help or harm? Arthritis Rheum (2012) 64:2417-2425.
14. Ware MA, Adams H, and GW Guy. The medicinal use of cannabis in the UK: results of a nationwide survey. International Journal of Clinical Practice (2005) 59:291-295.
15. Swift W, Gates P, and P Dillon. Survey of Australians using cannabis for medical purposes. Harm Reduct J (2005) 2:18.
16. Blake DR, Robson P, Ho M et al., Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (2006) 45:50-2.
17. Ware MA, Fitzcharles MA, Joseph L and Y Shir. The effects of nabilone on sleep in fibromyalgia: Results of a randomized controlled trial. Anesthesia and Analgesia (2010) 110:604-610.
18. Skrabek RQ, Galimova L, Ethans K and D Perry. Nabilone for the Treatment of Pain in Fibromyalgia. Journal of Pain (2008) 9:164-173.
19. Fitzcharles, M., et al., Rheumatologists lack confidence in knowledge of cannabinoids in the management of rheumatic conditions: a needs assessment of Canadian rheumatologists. Arthritis & Rheumatism (2013) 65:S49.
20. Taylor DR and W Hall. Respiratory health effects of cannabis: position statement of the Thoracic Society of Australia and New Zealand. Intern Med J (2003) 33:310-313.
21. Aldington S, Harwood M, Cox B et al., Cannabis use and risk of lung cancer: a case-control study. Eur Respir J (2008) 31:280-286.
22. Callaghan RC, Allebeck P, and A Sidorchuk. Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control (2013).
23. Cooper ZP and M Haney. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend (2009) 103:107-113.
24. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. CMAJ (2010) 182:E694-701.
25. Cascini F, Aiello C, and G Di Tanna. Increasing delta-9-tetrahydrocannabinol (Delta-9-THC) content in herbal cannabis over time: systematic review and meta-analysis. Curr Drug Abuse Rev (2012) 5:32-40.
26. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol (2005) 168:657-690.
27. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers (2007) 4:1770-1804.
28. Mensinga TT, deVries I, Kruidenier M, et al. A double-blind, randomized, placebo controlled, cross-over study on the pharmacokinetics and effects of cannabis. (2006) Nationaal Vergiftigingen Informatie Centrum, RIVM Report 267002002. p. 1-52.
29. Asbridge M, Hayden JA, and JL Cartwright. Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. BMJ (2012) 344:e536.(doi): p. 10.1136/bmj.e536.
30. Canada, D.o.J. Acts, Regulations, Health. Marihuana Medical Access Regulations (SOR/2001-227), P.C. 2001-1146 2001-06-14. http://lois-laws.justice.gc.ca/eng/regulations/SOR-2001-227/FullText.html 2013 2013-09-21.
31. Aryana A and MA Williams. Marijuana as a trigger of cardiovascular events: speculation or scientific certainty? Int J Cardiol (2007) 118:141-144.
32. Thornicroft G. Cannabis and psychosis. Is there epidemiological evidence for an association? Br J Psychiatry (1990) 157:25-33.
33. Moreira FA, Grieb M, and B Lutz. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab (2009) 23:133-144.
34. Harder VS, Morral AR and J Arkes. Marijuana use and depression among adults: Testing for causal associations. Addiction, 2006. 101(10): p. 1463-72.
35. Johns A. Psychiatric effects of cannabis. Br J Psychiatry (2001). 178:116-122.
36. van der Pol P, Liebregts N, de Graaf R et al., Predicting the transition from frequent cannabis use to cannabis dependence: A three-year prospective study. Drug Alcohol Depend (2013).
37. Smith MJ, Cobia DJ, Wang L et al., Cannabis-Related Working Memory Deficits and Associated Subcortical Morphological Differences in Healthy Individuals and Schizophrenia Subjects. Schizophr Bull (2013) 15: 15.